Quest Diagnostics (DGX, Financial) has retained its Neutral rating, according to recent analyst data. The rating was maintained by UBS analyst Kevin Caliendo on July 18, 2025. This suggests a steady outlook for the stock in the near term.
The price target for Quest Diagnostics (DGX, Financial) has been slightly lowered from $176.00 to $175.00 USD. This adjustment represents a marginal change of -0.57% in the price target. Despite this small decrease, the neutral rating was sustained, indicating balanced expectations for the stock's performance.
As the market continues to assess the implications of this update, Quest Diagnostics (DGX, Financial) remains under observation for any further developments that could impact its valuation or investor sentiment.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 16 analysts, the average target price for Quest Diagnostics Inc (DGX, Financial) is $184.61 with a high estimate of $200.00 and a low estimate of $158.69. The average target implies an upside of 10.69% from the current price of $166.78. More detailed estimate data can be found on the Quest Diagnostics Inc (DGX) Forecast page.
Based on the consensus recommendation from 20 brokerage firms, Quest Diagnostics Inc's (DGX, Financial) average brokerage recommendation is currently 2.2, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Quest Diagnostics Inc (DGX, Financial) in one year is $164.26, suggesting a downside of 1.51% from the current price of $166.78. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Quest Diagnostics Inc (DGX) Summary page.
